Evidence map›Paper›PMID 32175029›Full record

ArticleCellular and molecular bioengineering2020

A Stable Pep2-proapoptotic Peptide Inducing Apoptosis of Acute Myeloid Leukemia Cells by Down-Regulating EZH2.

Yanli Sun, Jiaqiu Li, Yanhua Sun, Ronglan Zhao, Lujuan Wang, Wei Song, Zhanzhao Wang, Jialing Wang, Liuya Wei, Yao Zhao and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular bioengineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yanli Sun *Department of Laboratory Medicine, Weifang Medical University, Weifang, China.ORCID 0000-0002-8883-5226
Jiaqiu Li *Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, China.
Yanhua SunDepartment of Hematology, Weifang People's Hospital, Weifang, China.
Ronglan ZhaoDepartment of Laboratory Medicine, Weifang Medical University, Weifang, China.
Lujuan WangDepartment of Laboratory Medicine, Weifang Medical University, Weifang, China.
Wei SongDepartment of Laboratory Medicine, Weifang Medical University, Weifang, China.
Zhanzhao WangDepartment of Laboratory Medicine, Weifang People's Hospital, Weifang, China.
Jialing WangSchool of Bioscience and Technology, Weifang Medical University, Weifang, China.
Liuya WeiSchool of Pharmacy, Weifang Medical University, Weifang, China.
Yao ZhaoDepartment of Laboratory Medicine, Weifang People's Hospital, Weifang, China.
Yang SongDepartment of Laboratory Medicine, Weifang Medical University, Weifang, China.
Zhenbo HuDepartment of Hematology, Affiliated Hospital of Weifang Medical University, Weifang, China.
Weifang Medical University · CNWeifang People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProapoptotic peptide, (KLAKLAK)

methodsHere, we evaluated the feasibility of PP7 VLPs carrying Pep2 and (KLAKLAK)

results2PP7-Pep2-KLAK VLPs was expressed in

conclusionsWe identified the feasibility to prepare the stable, active Pep2-KLAK peptide by using PP7 bacteriophage as the vehicle. We revealed this peptide was an inhibitor of EZH2. 2PP7-Pep2-KLAK VLPs may have significant clinical implications in the treatment of MLL-AF9 AML as an epigenetic modulator.

Indexed as

Acute myeloid leukemiaEnhancer of zeste homolog 2 (EZH2)PP7 bacteriophageProapoptotic peptideToll-like receptor 2 (TLR2)Virus-like particle (VLP)

Identifiers

PMID32175029
PMCPMC7048892
OpenAlexW2991775645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.